Semus Wealth Partners LLC Decreases Position in Johnson & Johnson (NYSE:JNJ)

Semus Wealth Partners LLC decreased its stake in Johnson & Johnson (NYSE:JNJ) by 3.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,261 shares of the company’s stock after selling 454 shares during the period. Johnson & Johnson makes up 1.3% of Semus Wealth Partners LLC’s portfolio, making the stock its 16th biggest position. Semus Wealth Partners LLC’s holdings in Johnson & Johnson were worth $1,825,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently modified their holdings of the company. China Universal Asset Management Co. Ltd. acquired a new position in shares of Johnson & Johnson in the first quarter worth about $765,000. Empowered Funds LLC raised its stake in Johnson & Johnson by 46.7% during the first quarter. Empowered Funds LLC now owns 101,237 shares of the company’s stock valued at $16,015,000 after buying an additional 32,244 shares in the last quarter. Jupiter Asset Management Ltd. acquired a new stake in Johnson & Johnson during the first quarter valued at approximately $718,000. Allstate Corp raised its stake in Johnson & Johnson by 9.2% during the first quarter. Allstate Corp now owns 7,940 shares of the company’s stock valued at $1,256,000 after buying an additional 668 shares in the last quarter. Finally, Edgestream Partners L.P. raised its stake in Johnson & Johnson by 18.4% during the first quarter. Edgestream Partners L.P. now owns 30,821 shares of the company’s stock valued at $4,876,000 after buying an additional 4,779 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $153.97 on Monday. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The firm has a market cap of $370.70 billion, a price-to-earnings ratio of 22.29, a P/E/G ratio of 2.74 and a beta of 0.53. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $168.85. The business has a fifty day simple moving average of $161.35 and a 200 day simple moving average of $156.13.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, topping the consensus estimate of $2.21 by $0.21. The firm had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The business’s quarterly revenue was up 5.2% on a year-over-year basis. During the same period in the prior year, the business posted $2.66 earnings per share. As a group, sell-side analysts predict that Johnson & Johnson will post 9.93 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.22%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 71.78%.

Insider Buying and Selling

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the transaction, the vice president now owns 18,973 shares in the company, valued at $3,131,683.38. This trade represents a 22.90 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.16% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Daiwa Capital Markets cut Johnson & Johnson from an “outperform” rating to a “neutral” rating and cut their price objective for the company from $160.00 to $150.00 in a research note on Tuesday, July 23rd. Citigroup upped their price objective on Johnson & Johnson from $180.00 to $185.00 and gave the company a “buy” rating in a research note on Wednesday, October 16th. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Morgan Stanley upped their price objective on Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. Finally, Guggenheim increased their price target on Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 6th. Seven research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $175.94.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.